[8][6][3][2] It is closely related to DOM and is a synthetic analogue of the naturally occurring phenethylamine psychedelic mescaline.

[12] It was clinically studied at low and sub-hallucinogenic doses for potential use as a pharmaceutical drug acting as a "psychic energizer" by Dow Chemical Company in the 1960s.

[12] However, its development was terminated after DOM emerged as a street drug and caused a public health crisis in San Francisco in 1967.

[4][14][17] In a 1968 clinical trial, DOET at an oral dose of 1.5 mg (as the hydrochloride salt) produced mild euphoria and enhanced self-awareness, but no hallucinogenic effects (in terms of perceptual distortions or hallucinations/open-eye visuals), marked behavioral changes, or intellectual impairment.

[3][15] DOET appeared to show a greater apparent separation between threshold and hallucinogenic doses than had been documented for other psychedelics.

[20][6] In line with notions that DOET is a "psychic energizer", the related drug DOPR has shown pro-motivational effects in rodents at sub-hallucinogenic doses[21][22] and the related drug Ariadne has reportedly shown pro-motivational effects in monkeys despite being non-hallucinogenic.

[10] The drug's EC50Tooltip half-maximal effective concentration for activation of the serotonin 5-HT2A receptor was 1.7 to 8.1 nM depending on the intracellular signaling cascade, while its EmaxTooltip maximal efficacy was 99%.

[29] The drug induces the HTR to a similar maximal extent as other related psychedelics like DOM and DOI.

[2][9] Analogues of DOET include other DOx drugs such as DOM, DOPR, DOBU, DOAM, DOB, and DOI.

[12] They selected DOET as a promising compound and decided to move forward with clinical trials for potential use as a pharmaceutical drug.

[12][38][8][40] Dow Chemical Company tasked neuroscientist Solomon H. Snyder at Johns Hopkins University with clinically studying DOET.

[12] In 1967, DOM emerged as a street drug and LSD replacement with the name "STP" in San Francisco and caused a public health crisis.

[12] The DOET tablets he distributed could have very long durations (up to 3–4 days) and resulted in intense experiences, worrying physical side effects, and hospitalizations.

[12] It is unclear why Shulgin told Stanley about DOM and risked his professional career as well as the DOET clinical development.

[12][13] However, it might have been because Shulgin felt that DOM was a promising compound but was not being further pursued by Dow Chemical Company and would otherwise be forgotten.

[12][13] Dow Chemical Company terminated its clinical research program on DOET due to the DOM public health crisis.

[6][37] However, in contrast to DOET and other DOx drugs like DOM, Ariadne remained completely non-hallucinogenic even at very high doses, showing a hard ceiling to its psychoactive effects and a lack of recreational potential.

[6][37] Ariadne was patented and developed by Shulgin and Bristol Laboratories for potential use as an antidepressant and for a variety of other clinical indications in the 1970s.

[37] In 2023, Ariadne was found to exhibit reduced-efficacy partial agonism of the serotonin 5-HT2A receptor compared to DOM, and this was considered to account for its dramatically reduced hallucinogenic potential.

[2][4][14][5] Shulgin also described 2C-E as producing robust psychedelic effects in PiHKAL, though with much higher doses required than DOET.

[6][8] Internationally, DOET is a Schedule I controlled drug; under the Convention on Psychotropic Substances, it is legal only for medical uses or scientific research.

[47] DOET is classified as a Schedule I substance in the United States and is similarly controlled in other parts of the world.